Abstract In the setting of the raging COVID-19 pandemic, the search for innovative therapeutics is desperately sought after. As we learn more about the characteristics and metabolic health of patients and as our understanding of COVID-19 pathophysiology and treatment progresses, so is our understanding of medication effects that might increase disease severity. As of late, ACE inhibitors have been under investigation for a potential increase in illness severity due to ACE2 upregulation. Given our knowledge of other nutrient-pharmaceutical interactions, could the ACE inhibitor impact on COVID be due to something else? In this paper, we discuss the possibility that ACE inhibitors might be affecting COVID-19 patients by causing zinc insufficiency. KEY MESSAGES Zinc deficiency caused by chronic ACE inhibitor usage may exacerbate the pathogenicity of COVID-19 in susceptible patients. A multi-center study is needed to assess the zinc levels of patients with COVID-19 who are taking ACE inhibitors and other medications that may result in low zinc levels.
【저자키워드】 COVID-19, SARS-CoV-2, Zinc, Critical care, nutrition, ACEi, 【초록키워드】 Treatment, ACE2, knowledge, COVID-19 pandemic, disease severity, COVID, Health, Characteristics, pathophysiology, Patient, ACE inhibitor, pathogenicity, medication, inhibitor, interactions, ACE, COVID-19 patient, Illness severity, zinc deficiency, upregulation, susceptible patients, Effect, caused, increase in, affecting, exacerbate, patients with COVID-19, 【제목키워드】 angiotensin-converting enzyme inhibitor,